These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 6569064)

  • 41. [The clinical evaluation of the hypocholesterolemic effects of an inhibitor of cholesterol synthesis: mevalonic acid].
    Del Nero E; Aloe N; Augeri C; Avola F; Carta G; Cavagnaro A; De Grandi R; Gianfreda M; Magro GP; Mazzarello GP
    Clin Ter; 1992 Jul; 141(7):47-50. PubMed ID: 1505176
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The effects of mevinolin on serum cholesterol levels of rabbits with endogenous hypercholesterolemia.
    Kroon PA; Hand KM; Huff JW; Alberts AW
    Atherosclerosis; 1982 Jul; 44(1):41-8. PubMed ID: 6921995
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Treatment of heterozygous familial hypercholesterolemia: atorvastatin vs simvastatin.
    Bo M; Nicolello MT; Fiandra U; Mercadante G; Piliego T; Fabris F
    Nutr Metab Cardiovasc Dis; 2001 Feb; 11(1):17-24. PubMed ID: 11383320
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Beneficial effect of simvastatin in patients with drug resistant familial hypercholesterolaemia.
    Lewis-Barned NJ; Ball MJ
    N Z Med J; 1992 Jul; 105(938):284-6. PubMed ID: 1495661
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Combined drug therapy--cholestyramine and compactin--for familial hypercholesterolemia.
    Yamamoto A; Yamamura T; Yokoyama S; Sudo H; Matsuzawa Y
    Int J Clin Pharmacol Ther Toxicol; 1984 Sep; 22(9):493-7. PubMed ID: 6500769
    [TBL] [Abstract][Full Text] [Related]  

  • 46. How effective is drug therapy in heterozygous familial hypercholesterolemia?
    Illingworth DR
    Am J Cardiol; 1993 Sep; 72(10):54D-58D. PubMed ID: 8213497
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Residual effects of lovastatin and simvastatin on urinary mevalonate excretions in patients with familial hypercholesterolemia.
    Pappu AS; Bacon SP; Illingworth DR
    J Lab Clin Med; 2003 Apr; 141(4):250-6. PubMed ID: 12677170
    [TBL] [Abstract][Full Text] [Related]  

  • 48. 3-Hydroxy-3-methylglutaryl--coenzyme A reductase inhibitors in the treatment of hypercholesterolemia.
    Hoeg JM; Brewer HB
    JAMA; 1987 Dec; 258(24):3532-6. PubMed ID: 3316727
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Plasma lipoprotein(a) levels and LDL-cholesterol lowering response to statin therapy in patients with heterozygous familial hypercholesterolemia.
    Miltiadous G; Saougos V; Cariolou M; Elisaf MS
    Ann Clin Lab Sci; 2006; 36(3):353-5. PubMed ID: 16951279
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Pravastatin vs gemfibrozil in the treatment of primary hypercholesterolemia. The Italian Multicenter Pravastatin Study I.
    Crepaldi G; Baggio G; Arca M; Avellone G; Avogaro P; Bittolo Bon G; Bompiani GD; Capurso A; Cattin L; D'Alŏ G
    Arch Intern Med; 1991 Jan; 151(1):146-52. PubMed ID: 1898694
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Pediatric implications of heterozygous familial hypercholesterolemia. Screening and dietary treatment.
    Kwiterovich PO
    Arteriosclerosis; 1989; 9(1 Suppl):I111-20. PubMed ID: 2563219
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Rapid and substantial lowering of human serum cholesterol by mevinolin (MK-803), an inhibitor of hydroxymethylglutaryl-coenzyme A reductase.
    Tobert JA; Hitzenberger G; Kukovetz WR; Holmes IB; Jones KH
    Atherosclerosis; 1982 Jan; 41(1):61-5. PubMed ID: 6918220
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Regulation of hepatic receptor-dependent degradation of LDL by mevinolin in rabbits with hypercholesterolemia induced by a wheat starch-casein diet.
    Chao YS; Kroon PA; Yamin TT; Thompson GM; Alberts AW
    Biochim Biophys Acta; 1983 Nov; 754(2):134-41. PubMed ID: 6317039
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Effects of CS-514 on serum lipoprotein lipid and apolipoprotein levels in patients with familial hypercholesterolemia.
    Mabuchi H; Kamon N; Fujita H; Michishita I; Takeda M; Kajinami K; Itoh H; Wakasugi T; Takeda R
    Metabolism; 1987 May; 36(5):475-9. PubMed ID: 3106756
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Effects of probucol on homozygous cases of familial hypercholesterolemia.
    Yamamoto A; Matsuzawa Y; Kishino B; Hayashi R; Hirobe K; Kikkawa T
    Atherosclerosis; 1983 Aug; 48(2):157-66. PubMed ID: 6615580
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Induction of mRNA for low-density lipoprotein receptors in heterozygous Watanabe heritable hyperlipidemic rabbits treated with CS-514 (Pravastatin) and cholestyramine.
    Kume N; Kita T; Mikami A; Yokode M; Ishii K; Nagano Y; Kawai C
    Circulation; 1989 May; 79(5):1084-90. PubMed ID: 2496935
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Modulation of human lymphocyte responses by low density lipoproteins (LDL): enhancement but not immunosuppression is mediated by LDL receptors.
    Cuthbert JA; Lipsky PE
    Proc Natl Acad Sci U S A; 1984 Jul; 81(14):4539-43. PubMed ID: 6087331
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Therapeutic effects of ML-236B in primary hypercholesterolemia.
    Yamamoto A; Sudo H; Endo A
    Atherosclerosis; 1980 Mar; 35(3):259-66. PubMed ID: 7362699
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Time response of cholesterol synthesis inhibition by compactin-related compounds. In vitro quantitation of the "escape phenomenon".
    Sviridov DD; Endo A; Pavlov MY; Repin VS
    Lipids; 1993 Jun; 28(6):569-71. PubMed ID: 8355584
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Influence of mevinolin on experimental atherosclerosis in rabbits.
    Kritchevsky D; Tepper SA; Klurfeld DM
    Pharmacol Res Commun; 1981 Nov; 13(10):921-6. PubMed ID: 6918018
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.